Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin.
Alterations in triglyceride and cholesterol metabolism often accompany inflammatory diseases and infections. We studied the effects of endotoxin (lipopolysaccharide [LPS]) and cytokines on hepatic sphingolipid synthesis, activity of serine palmitoyltransferase (SPT), the first and rate-limiting enzyme in sphingolipid synthesis, and lipoprotein sphingolipid content in Syrian hamsters. Administration of LPS induced a 2-fold increase in hepatic SPT activity. The increase in activity first occurred at 16 hours, peaked at 24 hours, and was sustained for at least 48 hours. Low doses of LPS produced maximal increases in SPT activity, with half-maximal effect seen at approximately 0.3 microg LPS/100 g body weight. LPS increased hepatic SPT mRNA levels 2-fold, suggesting that the increase in SPT activity was due to an increase in SPT mRNA. LPS treatment also produced 75% and 2.5-fold increases in hepatic sphingomyelin and ceramide synthesis, respectively. Many of the metabolic effects of LPS are mediated by cytokines. Interleukin 1 (IL-1), but not tumor necrosis factor, increased both SPT activity and mRNA levels in the liver of intact animals, whereas both IL-1 and tumor necrosis factor increased SPT mRNA levels in HepG2 cells. IL- produced a 3-fold increase in SPT mRNA in HepG2 cells, and the half-maximal dose was 2 ng/mL. IL-1 also increased the secretion of sphingolipids into the medium. Analysis of serum lipoprotein fractions demonstrated that very low density lipoprotein, intermediate density lipoprotein, and low density lipoprotein isolated from animals treated with LPS contained significantly higher amounts of ceramide, glucosylceramide, and sphingomyelin. Taken together, these results indicate that LPS and cytokines stimulate hepatic sphingolipid synthesis, which results in an altered structure of circulating lipoproteins and may promote atherogenesis.
Memon
R A
RA
Department of Medicine, University of California, San Francisco, USA.
Holleran
W M
WM
Moser
A H
AH
Seki
T
T
Uchida
Y
Y
Fuller
J
J
Shigenaga
J K
JK
Grunfeld
C
C
Feingold
K R
KR
D000217:Acyltransferases / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D002518:Ceramides / Q000032:analysis / Q000096:biosynthesis*; D006224:Cricetinae; D016207:Cytokines / Q000494:pharmacology*; D004731:Endotoxins / Q000494:pharmacology*; D004926:Escherichia coli; D006801:Humans; D008074:Lipoproteins / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects*; D008099:Liver / Q000737:chemistry / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008647:Mesocricetus; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D051102:Serine C-Palmitoyltransferase; D013109:Sphingomyelins / Q000032:analysis / Q000096:biosynthesis*; D013268:Stimulation, Chemical; D014407:Tumor Cells, Cultured
D002518:Ceramides; D016207:Cytokines; D004731:Endotoxins; D008074:Lipoproteins; D012333:RNA, Messenger; D013109:Sphingomyelins; D000217:Acyltransferases; C495089:SPTLC2 protein, human; D051102:Serine C-Palmitoyltransferase